Live symbol workspace

PBE market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $89.61

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$85.13

Resistance

$94.09

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$89.61

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

38%

No prior-week baseline yet

Avg confidence across 5 calls in the last 7 days

What sources say

Neutral 1 article

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

PBE News Intelligence (1 articles)

AI-curated news influencing PBE price, sentiment, and trend

Explore All PBE News with AI Analysis

Economy

3 hours ago

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?

PBE surged 41% in one year but endured a 35% drawdown, while XLV's diversified approach delivered steadier gains with half …

Impact on PBE: The comparison between XLV and PBE may lead to capital rotation from …

The healthcare ETF XLV has demonstrated steadier gains and lower volatility compared to the biotech … High (70%)

View full analysis →

Yahoo Finance 70% confidence